Luis Ruiz Rivera
Ponce, PRNPI 1518066216
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,326 of the $81,493 with a category attached, or 82.6%. 14 manufacturers reported payments, led by AstraZeneca at 42.0% of the total. Reporting peaked in 2019 at $49,070 and has fallen 98.9% since, to $516 in 2025.
Across 236 payments — averaging $345.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- Johnson & Johnson$20K
- Merck$17K
- Sanofi-aventis U.S. LLC$6K
- AbbVie$2K
- Eli Lilly Export S.A. Puerto Rico Branch$409
- plus $1K from 8 others
Across 1 payment — averaging $1381.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Consulting fees$4,7256%
- Speaking & faculty fees$67,32683%
- Travel & lodging$2,7753%
- Food & beverage$6,6478%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $34,227 |
| Johnson & Johnson | 39 | $19,595 |
| Merck | 39 | $17,392 |
| Sanofi-aventis U.S. LLC | 23 | $6,190 |
| AbbVie | 19 | $2,349 |
| Eli Lilly Export S.A. Puerto Rico Branch | 19 | $409 |
| Boehringer Ingelheim | 8 | $319 |
| Abbott | 11 | $298 |
| Bayer Puerto Rico Inc. | 7 | $186 |
| Novo Nordisk | 8 | $148 |
| Dexcom, Inc. | 6 | $144 |
| Lilly USA, LLC | 1 | $100 |
| Amgen | 3 | $71 |
| Radius Health, Inc. | 1 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$32,937
- INVOKANA$18,598
- STEGLATRO$13,450
- SOLIQUA 100/33$4,848
- Synthroid$1,988
- JANUVIA$1,500
- JANUMET$1,500
- TOUJEO$338
- JARDIANCE$112
- SYNJARDY$112
- TRIJARDY XR$112
- FreeStyle Libre Pro$105
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 254 | $258,547 |
| MounjaroTirzepatide | 204 | $221,437 |
| SynthroidLevothyroxine Sodium | 1,563 | $175,723 |
| JanuviaSitagliptin Phosphate | 129 | $146,857 |
| FarxigaDapagliflozin Propanediol | 84 | $96,859 |
| OzempicSemaglutide | 67 | $71,283 |
| JardianceEmpagliflozin | 45 | $56,874 |
| TrulicityDulaglutide | 51 | $51,662 |
| Xigduo XrDapaglifloz Propaned/Metformin | 37 | $43,349 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $37,941 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 38 | $31,020 |
| KerendiaFinerenone | 27 | $29,581 |
| TradjentaLinagliptin | 21 | $29,489 |
| LantusInsulin Glargine,hum.Rec.Anlog | 99 | $19,036 |
| JentaduetoLinagliptin/Metformin Hcl | 20 | $15,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $17,392 | $443,344416 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humalog Mix 75-25, Humulin N | $100 | $285,883312 claims |
| AbbVieSynthroid | $2,349 | $175,7231,563 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $319 | $101,64086 claims |
| AstraZenecaFarxiga | $34,227 | $96,85984 claims |
| Novo NordiskOzempic | $148 | $71,28367 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $6,190 | $50,056137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.